Bristol-Myers Squibb Company
Location
New Jersey
Founded
1887-04-10
Website
Risk Signals
10470 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Bristol-Myers Squibb Company
Live alerts from global media, monitored by Business Radar
2025-03-15 (bioprocessintl.com)
Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain
Bristol-Myers Squibb says it expects viral vector supply to ramp up later in the year as third-party and inhouse capacity come online.
Read more
2018-10-22 (marketwatch.com)
Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug
Bristol-Myers Squibb Co. undefined shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information...
Read more
2018-10-22 (marketwatch.com)
Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug
Bristol-Myers Squibb Co. undefined shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information...
Read more
(biospace.com)
FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment
The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.
Read more
(biospace.com)
FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment
The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.
Read more
(biospace.com)
FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment
The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.
Read more
(fiercepharma.com)
BeiGene's supply of Bristol Myers Squibb's Abraxane freezes in China amid Fresenius Kabi plant woes
It’s not very often you hear about manufacturing problems at Western facilities slammed by Chinese authorities. | It’s not very often you hear about manufacturing problems at Western facilities slammed by Chinese authorities. But it just happened. Due to breaches found at a Fresenius Kabi site in the U.S., Bristol Myers' Abraxane supply to BeiGene in China has been put to an abrupt halt, threatening a $100-million-a-year business.
Read more